|
|
Article: Picoplatin: Poniard's next big thing in platinum therapies?(Lung Cancer Phase III Begins)(Clinical report)
- Article from:
- Bioworld Financial Watch
- Article date:
- May 14, 2007
- Author:
CopyrightCOPYRIGHT 2007 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Non-small-cell lung cancer gets most of the press, but the less common, small-cell tumors strike in about 25 percent of cases--and could provide an entry to the market followed by handsome revenues for the likes of Poniard Pharmaceuticals Inc. and would-be competitor Pharmion Corp.
At the start of the month, Poniard kicked off a pivotal Phase III trial testing picoplatin in SCLC called SPEAR (Study of Picoplatin Efficacy After Relapse), conducted under a special protocol assessment agreement with the FDA. The randomized, controlled study is enrolling about 400 patients who are refractory to--or who have progressed within six months of completing--treatment with ...